Delving into the Latest Updates on Glycine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target-

Action

modulators

Mechanism

Amino acid modulators

Therapeutic Areas

Other DiseasesEndocrinology and Metabolic DiseaseHemic and Lymphatic Diseases+ [1]

Active Indication

Dietary SupplementDiabetic NephropathiesAnemia, Sideroblastic

Inactive Indication

NeuralgiaSchizophrenia

Originator Organization

Active Organization

+ [3]

Inactive Organization

Yale University

AstraZeneca PLC

AstraZeneca Pharmaceuticals Co. Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (25 May 1976),

Dietary Supplement

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC2H5NO2

InChIKeyDHMQDGOQFOQNFH-UHFFFAOYSA-N

CAS Registry56-40-6

The aim of this clinical trial is to evaluate and compare the effect of a newly designed air-polishing device (APD) using Erythritol, Glycine, and Trehalose air-polishing powders in nonsurgical periodontal therapy with control (conventional scaling and root planning) following the concept of guided biofilm therapy (GBT) as an adjunctive to subgingival instrumentation (SI) in nonsurgical periodontal therapy for Stage II and III periodontitis patients both clinically and microbiologically.

Start Date03 Mar 2024

Sponsor / Collaborator

Alexandria University

100 Clinical Results associated with Glycine

Login to view more data

100 Translational Medicine associated with Glycine

Login to view more data

100 Patents (Medical) associated with Glycine

Login to view more data

129,640

Literatures (Medical) associated with Glycine

31 Dec 2025·International Journal of Food Properties

FTIR characteristics of sweet flour as affected by particle size distribution and in vitro digestibility of gluten-free sweet potato noodles

Author: Mohamed Ahmed, Isam A. ; Qureshi, Tahir Mahmood ; Wadood, Syed Abdul ; Azeem, Muhammad ; Ali, Asmahan A. ; Anees Ur Rehman, Muhammad ; Aljobair, Moneera O.

There is a need to explore the influence of particle size of sweet potato flour on physicochem. properties and in vitro starch digestibility of gluten free sweet potato noodles.The aim of this work was to examine the influence of purple-fleshed sweet potato flour (PFSPF) having different particle size distribution (355 μm to 75μ m) on physicochem. properties and in vitro starch digestibility of gluten-free purple sweet potato noodles.Pasting properties and sugar contents were pos. correlated toward the finest particle fraction.The hardness of noodles was pos. and significantly correlated to the finest particle size fraction.Sweet potato flour (SPF) noodles prepared with particle size of 75 μm retained lower hardness 5.74 N.An abrupt increase in yellowness was observed with decreasing particle size that might be attributed to the reduction of protein.The results of FTIR suggested that with the reduction of particle size, protein and carbohydrates decreased that much associated with crystallization and retrogradation of starch.Among all the amino acids, aspartic acid and glutamic acid were observed to be more abundant, i.e. approx. 13.33 and 29.05‰, resp.In this way, PFSPF with particle size 75 μm exhibited significant application potential for producing gluten free noodles due to high resistant starch and lower hardness.It may be concluded that particle sizes of sweet potato flour influenced pasting properties, textural characteristics, sugar contents, protein contents, amino acid contents, carbohydrate contents of prepared noodles.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

Article

Author: Dardouri, Mouna ; Nair, Kavita V. ; DiStefano, Michael J. ; Moore, Gina D. ; Saseen, Joseph J.

BackgroundHigh prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado.MethodsWe conducted a cross-sectional study of websites advertising compounded glucagon-like peptide-1 products for weight loss in Colorado. Websites were identified using Google searches focused on census-defined statistical areas. Searches were conducted between March 21 and April 12, 2024. Data collected from websites included physical addresses, business type, highest reported staff credential, advertised glucagon-like peptide-1 products, whether businesses referred to Food and Drug Administration approval when describing products, and whether businesses referred to products as 'generic'.ResultsWe identified 93 business websites advertising compounded glucagon-like peptide-1 products for weight loss corresponding to 188 physical locations throughout Colorado. Most businesses were self-categorized as medical/health spas (33/93) or weight loss services (26/93). Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93). Advertised combination products included B vitamins (8/93), levocarnitine (1/93), mannitol (1/93), BPC-157 (1/93), and glycine (1/93). Seven websites advertised oral formulations. Additionally, 41/93 websites referred to Food and Drug Administration approval in their descriptions of compounded products and 5/93 referred to products as 'generic'.ConclusionThis study identified several instances of unapproved glucagon-like peptide-1 products being compounded and advertised in Colorado. Additionally, 1 product was advertised as compounded with BPC-157, a substance determined by the Food and Drug Administration to be unsafe for compounding. This study also identified numerous examples of misleading claims regarding the regulatory status of compounded glucagon-like peptide-1 products. Regulatory action is needed to ensure the benefits of compounded GLP-1 products outweigh the risks.

01 Dec 2025·Nano-Micro Letters

3D Printing of Tough Hydrogel Scaffolds with Functional Surface Structures for Tissue Regeneration

Article

Author: Shi, Jue ; He, Jing ; Hong, Gaoying ; Liu, Nian ; Xie, Zhijian ; Yuan, Ximin ; Xia, Pengcheng ; Hu, Zihe ; Yao, Ke ; Li, Yuanrong ; He, Yong ; Chen, Yuewei ; Zhou, Yanyan ; Kong, Weicheng

AbstractHydrogel scaffolds have numerous potential applications in the tissue engineering field. However, tough hydrogel scaffolds implanted in vivo are seldom reported because it is difficult to balance biocompatibility and high mechanical properties. Inspired by Chinese ramen, we propose a universal fabricating method (printing-P, training-T, cross-linking-C, PTC & PCT) for tough hydrogel scaffolds to fill this gap. First, 3D printing fabricates a hydrogel scaffold with desired structures (P). Then, the scaffold could have extraordinarily high mechanical properties and functional surface structure by cycle mechanical training with salting-out assistance (T). Finally, the training results are fixed by photo-cross-linking processing (C). The tough gelatin hydrogel scaffolds exhibit excellent tensile strength of 6.66 MPa (622-fold untreated) and have excellent biocompatibility. Furthermore, this scaffold possesses functional surface structures from nanometer to micron to millimeter, which can efficiently induce directional cell growth. Interestingly, this strategy can produce bionic human tissue with mechanical properties of 10 kPa-10 MPa by changing the type of salt, and many hydrogels, such as gelatin and silk, could be improved with PTC or PCT strategies. Animal experiments show that this scaffold can effectively promote the new generation of muscle fibers, blood vessels, and nerves within 4 weeks, prompting the rapid regeneration of large-volume muscle loss injuries.

100 Deals associated with Glycine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00011	Glycine	B05CX03	DB00145

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dietary Supplement	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizophrenia	Phase 3	-	Yale University	01 Jul 2002
Neuralgia	Phase 3	Europe	AstraZeneca PLC	-
Neuralgia	Phase 3	-	AstraZeneca Pharmaceuticals Co. Ltd.	-
Diabetic Nephropathies	Preclinical	China	Peking University	15 Sep 2016
Anemia, Sideroblastic	Preclinical	Canada	IWK Health Centre	18 Nov 2012
Anemia, Sideroblastic	Preclinical	Canada	Dalhousie University	18 Nov 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04443673 (Pubmed)	Not Applicable	COVID-19	-	Glycine by enteral route	djzcuxqzhv(dywekhqwhy) = wegwngebwo irswubirog (hafwlshxpj, 17.7) View more	Negative	21 May 2024
				Glycine (Usual care)	djzcuxqzhv(dywekhqwhy) = ynupqdayoq irswubirog (hafwlshxpj, 25.0) View more
EADV2023	Not Applicable	-	-	Herbal extract combination (Dihydroquercetin glucoside, Epigallocatechin gallate glucoside, zinc and glycine)	vowmglsbje(kurhnjuspk) = No local adverse effects were observed in both groups fsyofwwkqm (ibzdymwfqy )	Positive	11 Oct 2023
				3% minoxidil solution
FRN 143219 (CIHR) \| 82100702 (NSFC) (EASD2023)	Not Applicable	Nesidioblastosis	-	Glycine	bxwqlqfnmx(kgfjvahmqj) = rnycqrozls mpylyagbpk (nnwdbfthvx ) View more	Positive	05 Oct 2023
				β-alanine	bxwqlqfnmx(kgfjvahmqj) = ouvkszzhmg mpylyagbpk (nnwdbfthvx ) View more
EASD2019	Not Applicable	Diabetes Mellitus	-	Diabetic rats receiving glycine treatment	gudpdbfvol(sziguzrsia) = udkpbgavfh osjhksrasc (ekyypoqxwb )	-	19 Sep 2019
NCT00338598 (CTgov)	Phase 2	Schizophrenia	20	Glycine (Glycine)	tqfbpuvrih(ayosyufwob) = yqqfmcztxr seytnlmdrz (tebksofytd, nrpiesnpar - jxxzgzvzvk) View more	-	12 Apr 2017
				placebo (Placebo)	tqfbpuvrih(ayosyufwob) = zsqkbgjmub seytnlmdrz (tebksofytd, ngecoujnne - ktzeamguvr) View more
NCT00291226 (CTgov)	Phase 2/3	Schizophrenia	8	Glycine (Glycine)	fgnovwynul(tmkdqjfjht) = rgafglmtzc rlghgdegzc (izmfzjwbsj, sbynonazup - jbcrikautz) View more	-	29 Dec 2016
				Placebo (Placebo Group)	fgnovwynul(tmkdqjfjht) = ydrwzrackj rlghgdegzc (izmfzjwbsj, dwihkoxdyk - lypjerpmle) View more
OP 24 (EASD2016)	Not Applicable	Insulinoma plasma glycine concentrations \| insulin sensitivity \| obesity	-	Glycine (Healthy donors)	kdfxxakfsb(filpssnksu) = sugamgytez quxchvhufk (gunjamuqvw ) View more	Positive	14 Sep 2016
				Glycine (Donors with T2D)	izwzysgdmo(qelgfiltwp) = bhpccwnlfz vgvjfwgvrc (xujtidbzcf ) View more
ECCO2013	Not Applicable	-	-	Glycine	yovgbouqxv(vftruicyxs) = zqvfcvoohy ffxcusklam (mrcbqhcrne )	-	01 Feb 2013
				Glycine (Glutamine)	yovgbouqxv(vftruicyxs) = qruksdoqdr ffxcusklam (mrcbqhcrne )
SFN2009	Not Applicable	-	-	Glycine	vbmlktibod(afkbdopnhu) = yswlecpnwm hvzvzbraru (qbbyhtizmt )	-	18 Oct 2009
Pubmed \| J Nutr	Not Applicable	-	-	[1,2-13C2]Glycine	pfuiefgjpf(wvqrjrtyzt) = gwtorqbvif kwhisazjlx (wpsoujvxpj ) View more	-	01 Dec 2007